Clinical trial
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to…
NCT00481676 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00481676 |
|---|---|
| Title | Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria |
| Official title | A Randomized, 24 Weeks, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of Omalizumab in Adult Patients With Chronic Urticaria Who Exhibit IgE Against Thyroperoxidase |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Urticaria |
| Intervention type | Drug |
| Interventions | Omalizumab 75-375 mg, Placebo to omalizumab, Loratadine, Clemastine |
| Enrollment | 49 |
| Start date | May 1, 2007 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Jun 4, 2007 |
| Last update posted | Oct 21, 2011 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: